Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy
Ziyang Zhang, Peter J. Rohweder, Chayanid Ongpipattanakul, et al.
Cancer Cell (2022) Vol. 40, Iss. 9, pp. 1060-1069.e7
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Neoantigens: promising targets for cancer therapy
Na Xie, Guobo Shen, Wei Gao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 439
The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 119
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Míriam Molina‐Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 46
Unveiling the role of KRAS in tumor immune microenvironment
Miao Xu, Xing Zhao, Ti Wen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116058-116058
Open Access | Times Cited: 24
Combinatorial strategies to target RAS-driven cancers
Naiara Perurena, Lisa Situ, Karen Cichowski
Nature reviews. Cancer (2024) Vol. 24, Iss. 5, pp. 316-337
Closed Access | Times Cited: 22
Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy
Takamitsu Hattori, Lorenzo Maso, Kiyomi Y. Araki, et al.
Cancer Discovery (2022) Vol. 13, Iss. 1, pp. 132-145
Open Access | Times Cited: 52
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Guowei Yin, Jing Huang, Johnny Petela, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 27
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells
Jianping Li, Zhiwen Xiao, Donghui Wang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 27
Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions
Alex Watterson, Matthew A. Coelho
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 23
The Future of Precision Oncology
Stuart L. Rulten, Richard Grose, Susanne A. Gatz, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12613-12613
Open Access | Times Cited: 23
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
Caicun Zhou, Chongyang Li, Libo Luo, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1286-1300.e8
Closed Access | Times Cited: 11
Targeting macrophages in cancer immunotherapy: Frontiers and challenges
Yue Liu, Huabing Tan, Jingyuan Dai, et al.
Journal of Advanced Research (2025)
Open Access | Times Cited: 1
Exosomal miR-625-3p secreted by cancer-associated fibroblasts in colorectal cancer promotes EMT and chemotherapeutic resistance by blocking the CELF2/WWOX pathway
Ying Zhang, Changjun Yin, Chao Wei, et al.
Pharmacological Research (2022) Vol. 186, pp. 106534-106534
Closed Access | Times Cited: 31
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance
Martin Sattler, Atish Mohanty, Prakash Kulkarni, et al.
Trends in cancer (2022) Vol. 9, Iss. 1, pp. 42-54
Open Access | Times Cited: 28
Chemical technology principles for selective bioconjugation of proteins and antibodies
Preeti Chauhan, V. Ragendu, Mohan Kumar, et al.
Chemical Society Reviews (2023) Vol. 53, Iss. 1, pp. 380-449
Closed Access | Times Cited: 19
RAS‐targeted cancer therapy: Advances in drugging specific mutations
Cen Liu, Danyang Ye, Hongliu Yang, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 18
Unlocking the potential of microfluidics in mass spectrometry-based immunopeptidomics for tumor antigen discovery
Charlotte Stutzmann, Jiaxi Peng, Zhaoguan Wu, et al.
Cell Reports Methods (2023) Vol. 3, Iss. 6, pp. 100511-100511
Open Access | Times Cited: 18
Mutation Patterns Predict Drug Sensitivity in Acute Myeloid Leukemia
Guangrong Qin, Jin Dai, Sylvia Chien, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 12, pp. 2659-2671
Open Access | Times Cited: 7
The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
Yuko Oya, Kazuyoshi Imaizumi, Tetsuya Mitsudomi
Lung Cancer (2024) Vol. 194, pp. 107886-107886
Open Access | Times Cited: 7
Targeting RAF dimers in RAS mutant tumors: From biology to clinic
Huanhuan Yin, Qiulin Tang, Hongwei Xia, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 5, pp. 1895-1923
Open Access | Times Cited: 6
Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC
Chiara Musiu, Francesca Lupo, Antonio De Agostini, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment
Douglas Hanahan, Olivier Michielin, Mikaël J. Pittet
Nature reviews. Cancer (2024)
Closed Access | Times Cited: 6
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
Targeting KRASG12C in colorectal cancer: the beginning of a new era
Davide Ciardiello, Brigida Anna Maiorano, Erika Martinelli
ESMO Open (2022) Vol. 8, Iss. 1, pp. 100745-100745
Open Access | Times Cited: 24
The biogenesis of the immunopeptidome
Arie Admon
Seminars in Immunology (2023) Vol. 67, pp. 101766-101766
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top